|
 |
IdamycinThis page contains recent news articles, when available, and an overview of Idamycin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Idamycin (when available) Idarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific. For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. Mechanism Of Action: Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. News Articles on Idarubicin Teva, Pfizer Reach Patent Deal - Nov 21, 2006 Idarubicin is sold under the brand name Idamycin by Pfizer. The company markets azithromycin as Zithromax. Teva will continue to market its generic versions ... TheStreet.com - TheStreet.com (subscription) Analysis: Shake-up in the leukemia market. - Oct 16, 2006 ..."In 2005, Pfizer's Idamycin/Zavedos occupied the largest share of the total AML market," ... Idamycin/Zavedos, which currently has 27 percent of the market, ... Free with registration - UPI Health Business - AccessMyLibrary.com Pfizer settles with Novartis in Zithromax lawsuit - Jul 6, 2007 Israel's Teva Pharmaceutical Industries said it would pay Pfizer as much as $70 million for rights to make copies of Zithromax and cancer drug Idamycin. ... Medical Marketing & Media - Medical Marketing and Media כלכלה nrg - ...טבע תשל×? לפייזר 70 מליון דולר במסגרת הסכ×? - Nov 21, 2006 ...מדובר בתרופה של פייזר לסרטן- Idamycin וה×?× ×˜×™×‘×™×•×˜×™×§×” שלה Zithromax. כחלק מההסכ×? תשל×? טבע עד 70 ... NRG מעריב Pfizer Defends Chemotherapy-Drug Patent in Trial Against Teva - Nov 20, 2006 The ready-to-use injectable Idamycin solution is ``neither novel science nor a response to any long-felt need,'' Sicor lawyer Reid Ashinoff, of New York's ... Bloomberg Miami Herald, The : RECAPITALIZATION OFFER FOR MILLS CORP. … - Nov 22, 2006 The disputes concerned Pfizer's cancer medication Idamycin and its antibiotic ... Teva will be able to continue selling its generic version of Idamycin and ... $2.95 - Miami Herald - NewsBank Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 4, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased with doxorubicin, daunorubicin, or idamycin," test results showed. ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 4, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased with doxorubicin, daunorubicin, or idamycin," test results showed. ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 5, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased with doxorubicin, daunorubicin, or idamycin," test results showed. ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 5, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased with doxorubicin, daunorubicin, or idamycin," test results showed. ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Press Release: Pfizer Announces Settlement With Teva on Patents … - Nov 21, 2006 Teva that resolves two separate lawsuits alleging patent infringement of Pfizer's cancer medication, Idamycin, and its antibiotic, Zithromax. ... Pay-Per-View - PR Newswire - HighBeam Research Pfizer and Teva resolve two law suits. - Nov 27, 2006 The agreement will end Pfizer's litigation against Teva and the latter's Sicor unit, over its sales of generic Idamycin, as well as Teva's sales of ... $9.94 - Pharma Marketletter - Alacra Store Pfizer Settles Suit With Novartis Over Zithromax Drug - Jul 5, 2007 ...world's biggest generic- drugmaker, said it would pay Pfizer as much as $70 million for rights to make copies of Zithromax and the cancer drug Idamycin. ... Bloomberg Mitoxantrone Injection Side Effects from Consumer Reports Health. - Jan 4, 2008 ...doxorubicin (Doxil), epirubicin (Ellence), or idarubicin (Idamycin), or if you have ever been treated with mitoxantrone in the past. ... consumerreports.org How to take Bevacizumab Injection from Consumer Reports Health. - Jan 12, 2008 ...epirubicin (Ellence), or idarubicin (Idamycin). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. ... consumerreports.org Pfizer said it will halt all clinical trials for torcetrapib, the... - Jan 1, 2007 Teva that resolves two separate lawsuits alleging patent infringement of Pfizer's cancer medication, Idamycin, and its antibiotic, Zithromax. ... $9.94 - Medical Marketing & Media - Alacra Store Doxorubicin, Liposomal (Systemic). - Oct 27, 2005 Cerubidine) or Doxorubicin (eg, Adriamycin) or Idarubicin (eg, Idamycin) or Mitoxantrone (eg, Novantrone) -- Concurrent use of maximum cumulative doses ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Pfizer и Novartis урегулировали патентный Ñ?пор в отношении … - Jul 6, 2007 СШÐ? за право продавать дженериковые верÑ?ии Zithromax и противоопухолевого препарата Idamycin. Ð’ 2006 г. объем продаж Zithromax Ñ?оÑ?тавил 638 млн долл. СШÐ?. ... ФармацевтичеÑ?кий веÑ?тник Epirubicin (Systemic ).(Drug overview) - May 1, 2006 Daunorubicin (eg, Cerubidine) or Doxorubicin (eg, Adriamycin) or Idarubicin (eg, Idamycin) or Mitoxantrone (eg, Novantrone) -- Concurrent use of maximum ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Doxorubicin, Liposomal (Systemic).(Drug overview) - Aug 1, 2006 Cerubidine) or Doxorubicin (eg, Adriamycin) or Idarubicin (eg, Idamycin) or Mitoxantrone (eg, Novantrone) -- Concurrent use of maximum cumulative doses ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Use of Revlimid® Strong in First Quarter 2006 - May 22, 2006 Cytosar® combined with Idamycin® remains the preferred induction regimen for younger and older AML patients. An average of 5% of CLL patients were treated ... Cancer Consultants Epirubicin (Systemic ). - Feb 1, 2006 Daunorubicin (eg, Cerubidine) or Doxorubicin (eg, Adriamycin) or Idarubicin (eg, Idamycin) or Mitoxantrone (eg, Novantrone) -- Concurrent use of maximum ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Press Release: PFIZER INC - Teva and Pfizer's Zithromax. - PR... - Nov 21, 2006 Teva that resolves two separate lawsuits alleging patent infringement of Pfizer's cancer medication, Idamycin, and its antibiotic, Zithromax. ... Pay-Per-View - PR Newswire UK Disclose - HighBeam Research Press Release: Pfizer Announces Settlement With Teva on Patents … - Nov 22, 2006 ...with generic drug manufacturer Teva that resolves two separate lawsuits alleging patent infringement of Pfizer's cancer medication, Idamycin, and its . ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Increased Use of Wyeth's Mylotarg and Launches of New ... - Oct 16, 2006 Kingdom -- Pfizer's Idamycin/Zavedos -- will lose significant sales during the 2005-2015 study period as Mylotarg and Clolar become the market leaders. ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: Idamycin is also known by the following brand names and/or synonymsIDARUBICIN; Idamycin; Idamycin Pfs; Idarubicin; Idarubicin Aglycone; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin Hydrochloride; Idarubicina [Inn-Spanish]; Idarubicine [Inn-French]; Idarubicinum [Inn-Latin] Drug Category: Idamycin is categorized under the following by the FDA: Antibiotics; Antineoplastic Agents; ATC:L01DB06 Dosage Forms: POWDER FOR SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |